Science Explorer Back to mapMap
Discussion
Company · Écully · France

OREGA Biotech (France)

orega-biotech.comROR OpenAlex
Research works
8
▲ 5% vs 2018-21
Citations
339
42.8 per fractional work
Top-10% rate
7.9%
all institutions 10.0%
Open access
30%
world 40%
International
14%
world 18%
OREGA Biotech (France)

Not ranked overall: OREGA Biotech (France) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does OREGA Biotech (France) work in?

In all years, 43% of research at OREGA Biotech (France) is in Life Sciences, 38% in Health Sciences. Its largest fields are Medicine (38%), Biochemistry, Genetics and Molecular Biology (28%), Immunology and Microbiology (14%). It does 1.5× the world's share of Life Sciences.

Life Sciences: 3 fractional works · 42.7% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 28.3% of its workPhysiology: 1 fractional works · 16.1% of its workBiotechnology: 0 fractional works · 4.8% of its workGenetics: 0 fractional works · 4.2% of its workMolecular Biology: 0 fractional works · 2.1% of its workCancer Research: 0 fractional works · 1.1% of its workImmunology and Microbiology: 1 fractional works · 14.4% of its workImmunology: 1 fractional works · 14.4% of its workHealth Sciences: 3 fractional works · 38.2% of its workMedicine: 3 fractional works · 37.5% of its workOncology: 2 fractional works · 26.5% of its workPulmonary and Respiratory Medicine: 0 fractional works · 4.8% of its workEpidemiology: 0 fractional works · 2.9% of its workDermatology: 0 fractional works · 1.1% of its workPathology and Forensic Medicine: 0 fractional works · 0.8% of its workPsychiatry and Mental health: 0 fractional works · 0.6% of its workGenetics: 0 fractional works · 0.4% of its workTransplantation: 0 fractional works · 0.4% of its workHealth Professions: 0 fractional works · 0.6% of its workSpeech and Hearing: 0 fractional works · 0.6% of its workPhysical Sciences: 2 fractional works · 19.1% of its workEngineering: 1 fractional works · 10.7% of its workBiomedical Engineering: 1 fractional works · 6.6% of its workElectrical and Electronic Engineering: 0 fractional works · 4.2% of its workComputer Science: 0 fractional works · 4.2% of its workComputer Networks and Communications: 0 fractional works · 4.2% of its workPhysics and Astronomy: 0 fractional works · 4.2% of its workAtomic and Molecular Physics, and Optics: 0 fractional works · 4.2% of its workALL ITS WORKOREGA Biotech(France)8fractional works, all years
Life Sciences43%Physical Sciences19%Health Sciences38%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 7 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology228.3%
    2. Immunology and Microbiology114.4%
    1. Medicine337.5%
    2. Health Professions00.6%
    1. Engineering110.7%
    2. Computer Science04.2%
    3. Physics and Astronomy04.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

What are the most cited papers from OREGA Biotech (France)?

The most cited paper from OREGA Biotech (France) is "Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies" (Ivan Perrot et al., 2019), with 430 citations. Next come "Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen" (267) and "Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity" (255).

Most cited papers
#PaperReleasedCitations
1 Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Ivan Perrot et al. · Cell Reports Open access May 2019 430
2 Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Emeric Limagne, Romain Euvrard, Marion Thibaudin et al. · Cancer Research 5 Aug 2016 267
3 Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity Jérémy Bastid, Anne Regairaz, Nathalie Bonnefoy et al. · Cancer Immunology Research 17 Nov 2014 255
4 ENTPD1/CD39 is a promising therapeutic target in oncology Jérémy Bastid, A Cottalorda-Regairaz, Gilles F. Alberici et al. · Oncogene 2 Jul 2012 202
5 Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type Joseph Fabre, Jérôme Giustiniani, Christian Garbar et al. · International Journal of Molecular Sciences Open access 30 Aug 2016 172
All 21 most cited papers, with filters and sorting

Which research topics does OREGA Biotech (France) publish most on?

By volume in 2022-now: Advancements in PLL and VCO Technologies, Network Time Synchronization Technologies, Advanced Frequency and Time Standards and Microbial Inactivation Methods.

Advancements in PLL and …0Advancements in PLL and VCO Technologies: 0 fractional worksNetwork Time Synchroniza…0Network Time Synchronization Technologies: 0 fractional worksAdvanced Frequency and T…0Advanced Frequency and Time Standards: 0 fractional works
Electrical and Electronic EngineeringComputer Networks and CommunicationsAtomic and Molecular Physics, and Optics

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Advancements in PLL and VCO Technologies Electrical and Electronic Engineering 0 works
  2. 2 Network Time Synchronization Technologies Computer Networks and Communications 0 works
  3. 3 Advanced Frequency and Time Standards Atomic and Molecular Physics, and Optics 0 works
  4. 4 Microbial Inactivation Methods Biotechnology 0 works
  5. 5 Microfluidic and Bio-sensing Technologies Biomedical Engineering 0 works
  6. 6 3D Printing in Biomedical Research Biomedical Engineering 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available29.7%not open70.3%

World: 40% of research is openly available.

with international co-authors14.4%domestic only85.6%

World: 18% is written across borders.

How has OREGA Biotech (France)'s research output changed?

Output in 2022-2025 was 5% higher than in 2018-2021.

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is OREGA Biotech (France) as a percentage of every work published that year, 0.0000067% in 2020.

still counting0.000020%0.000040%0.000060%OREGA Biotech (France)0.000019% in 20252020

Fractional works of OREGA Biotech (France) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Écully

All research institutions in Écully

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about OREGA Biotech (France). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.